By Colin Kellaher
Essa Pharma's stock price plunged after the clinical-stage pharmaceutical company said it was throwing in the towel on its lead product candidate and exploring strategic alternatives.
Shares of the South San Francisco, Calif., company were down 63.5% at $1.90 in premarket trading Friday.
Essa late Thursday said it was ending Phase 2 study of masofaniten in prostate cancer after determining the study was unlikely to meet its primary endpoint.
The company said it would also terminate other studies involving masofaniten and launch a process to review strategic options focused on maximizing shareholder value.
Essa, which had a market capitalization of nearly $231 million based on Thursday's closing price of $5.20, said it had net working capital of $124.3 million as of Sept. 30.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 01, 2024 06:50 ET (10:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.